Choose a goal and an evidence bar. You get a ranked list with the reasons each peptide is on it, approved medicines first. Of the 88 compounds in the database, 31 have an approved product somewhere and 14 have only animal or cell data.
27 compounds in the database are studied for fat loss. 10 have an approved product, 14 more have human data, and 3 rest on animal or cell work alone.
An approved product exists, made under drug manufacturing rules and prescribed by a clinician. Check the indication: it may not be this goal.
A once-daily GLP-1 drug approved for type 2 diabetes (Victoza) and weight loss (Saxenda), now sold as generics.
The first GLP-1 drug, a copy of a Gila monster venom peptide, approved for type 2 diabetes in 2005. The brands are discontinued in the US.
A once-weekly GLP-1 receptor agonist approved for type 2 diabetes, obesity, heart risk, kidney disease and fatty liver disease.
A once-weekly GLP-1 drug from Eli Lilly (Trulicity) approved for type 2 diabetes and heart risk reduction, not for weight loss.
A once-weekly GIP and GLP-1 dual agonist approved for type 2 diabetes, heart risk in diabetes, obesity and sleep apnea.
An FDA-approved GHRH analog that shrinks visceral belly fat in people with HIV lipodystrophy. Not approved for weight loss.
A daily MC4R agonist (Imcivree) approved for rare genetic obesity and acquired hypothalamic obesity, not common obesity.
Lab-made human growth hormone. FDA-approved for growth failure and adult GH deficiency; distributing it for anti-aging is a federal crime.
Hanmi's weekly exendin-based GLP-1 drug, approved in South Korea for weight management in October 2026 as Eppe. Not FDA approved.
Weekly GLP-1 and glucagon dual agonist, approved in China in 2025 for weight management and type 2 diabetes; not approved in the US.
Human studies exist, but no regulator has approved a product. Quality and safety of what is sold online are unverified.
A mealtime amylin analog (Symlin) approved in 2005 for insulin users with diabetes. Every US strength is now discontinued.
Novo Nordisk's weekly shot that pairs the amylin analog cagrilintide with semaglutide. Under FDA review for obesity, not approved.
An investigational once-weekly GIP, GLP-1 and glucagon triple agonist from Eli Lilly, in late phase 3 for obesity. Not approved.
Investigational weekly injection that hits glucagon and GLP-1 receptors, studied for obesity and fatty liver disease (MASH).
Not a GLP-1 drug: an investigational once-weekly amylin analog from Novo Nordisk, studied alone and with the GLP-1 drug semaglutide as CagriSema. Not approved.
Altimmune's weekly GLP-1/glucagon dual agonist, now in phase 3 for fatty liver disease (MASH) and studied for obesity and alcohol use disorder.
Novo Nordisk's single-molecule GLP-1 and amylin agonist, now named zenagamtide, tested as a weekly shot and a daily pill. In phase 3, not approved.
16-amino-acid growth hormone fragment developed as an obesity pill; it failed its 536-person trial in 2007 and was never approved.
A 16-amino-acid piece of the tail of human growth hormone, tested as a fat-loss drug. Its human trials found no significant weight loss.
Zealand Pharma and Roche's once-weekly amylin analog for obesity, aimed at weight loss with less nausea than GLP-1 drugs. In phase 3.
Lilly's investigational weekly amylin-receptor agonist; up to 20% weight loss at 48 weeks in phase 2, now in phase 3.
A lab-modified version of the hormone that tells the pituitary to release growth hormone. Never approved; human data stop at dosing studies.
A five-amino-acid ghrelin-receptor agonist that releases growth hormone. Its only efficacy trial, for post-surgery gut paralysis, failed.
The active 29-amino-acid piece of growth hormone-releasing hormone. FDA-approved for children until its maker stopped selling it in 2008.
Every peptide record lists the goals it has been studied for, most relevant first. The finder keeps the ones that match your goal, including those where it is a side interest.
"Approved only" keeps molecules sold as an approved medicine somewhere. "Human evidence" adds anything tested in people. "Include animal-only" adds the rest.
Approved products always rank above unapproved ones, even when the unapproved one has a bigger trial. An approved product has passed manufacturing inspection and has a label with known side effects.
Within each group, stronger evidence grade comes first, then peptides where your goal is the main research focus, then the number of human studies.
Each bar is every compound studied for that goal, split by the strongest evidence behind it. Tap a goal for its full page.
One email when a new human trial is published, a label changes or the FDA acts on a peptide. We say what the result means and link the source.